Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab and Cemiplimab in Early-stage ER+ Breast Cancer
NCT05967884Phase 2Unknown
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of dupilumab in breast cancer, sponsored by Ottawa Hospital Research Institute. Status: unknown.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05967884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05967884.